210 related articles for article (PubMed ID: 35008821)
1. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
Vaishnavi A; Scherzer MT; Kinsey CG; Parkman GL; Truong A; Ghazi P; Schuman S; Battistone B; Garrido-Laguna I; McMahon M
Cell Rep; 2020 Aug; 32(5):107994. PubMed ID: 32755586
[TBL] [Abstract][Full Text] [Related]
3. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
4. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
5. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
9. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
[TBL] [Abstract][Full Text] [Related]
10. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
[TBL] [Abstract][Full Text] [Related]
11. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
[TBL] [Abstract][Full Text] [Related]
12. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
13. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
14. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
15. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
[TBL] [Abstract][Full Text] [Related]
16. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Rohrberg KS; Lassen U
Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
[TBL] [Abstract][Full Text] [Related]
17. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
18. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
[TBL] [Abstract][Full Text] [Related]
20. Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.
Sohn SH; Sul HJ; Kim B; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
